- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00525265
A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)
November 6, 2013 updated by: Otsuka Pharmaceutical Co., Ltd.
To investigate the pharmacokinetics, pharmacodynamics (urine volume and fluid intake), efficacy(body weight, pulmonary congestion and other congestions including cardiothoracic ratio) and safety of 7-day repeated oral administration of OPC-41061 at 7.5 mg or 15 mg in congestive heart failure (cardiac edema) patients with extracellular volume expansion despite the use of a diuretic.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kanto region, Japan
-
Kyushu region, Japan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 85 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects with cardiac edema receiving diuretic treatments 7 days prior to the start of treatment.
- Subjects able to receive a daily regular dosage of furosemide at 40-mg to 80-mg from the observation period until the end-of-treatment examination.
- CHF patients with lower limb edema, jugular venous distention, or pulmonary congestion due to extracellular volume expansion.
- Male or female subjects between the age of 20 and 85, inclusive.
- Subjects able to stay at the study site from the day before the start of the run-in observation period until completion of post-dosing examination 2.
- Subjects capable of giving informed consent to participate in the study of their own free will.
Exclusion Criteria:
- Subjects with heart failure with markedly fluctuating symptoms.
- Subjects with an assisted circulation device.
- Subjects with any of the following complications or symptoms:(1)Suspected decrease in circulatory blood flow,(2)Hypertrophic cardiomyopathy (other than dilated phase),(3)Cardiac valve disease with significant heart valve stenosis,(4)Hepatic coma.
- Subjects who develop acute myocardial infarction within 30 days prior to the screening examination.
- Subjects with well-defined diagnosis of active myocarditis or amyloid cardiomyopathy.
- Subjects with any of the following complications or symptoms:(1)Diabetes mellitus with poorly controlled blood glucose,(2)Anuria,(3)Urination impaired due to urinary tract stricture,urinary calculus,tumor in urinary tract,or other cause.
- Subjects with a history of any of the following diseases:(1)Sustained ventricular tachycardia or ventricular fibrillation within 30 days prior to the screening examination in patients without an implanted defibrillator,(2)Cerebrovascular disorder within 6 months prior to the screening examination (other than asymptomatic cerebral infarction),(3)Hypersensitivity or idiosyncratic reaction to benzazepine derivatives.
- Subjects who are morbidly obese (body mass index exceeding 35).
- Subjects with systolic blood pressure in the decubitus position below 90 mmHg.
- Subjects with any of the following abnormal laboratory values:(1)Total bilirubin > 3.0 mg/dL,(2) serum creatinine > 3.0 mg/dL,(3)serum sodium > 147 mEq/L,(4)serum potassium > 5.5 mEq/L.
- Subjects who are unable to take oral medication.
- Female subjects who are pregnant, possibly pregnant, or lactating, or who plan to become pregnant.
- Subjects who received any investigational drug other than OPC-41061 within 30 days prior to the screening examination.
- Subjects who previously participated in this or any other study of OPC-41061 and received OPC-41061.
- Subjects otherwise judged by the investigator or subinvestigator to be inappropriate for inclusion in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: 2
placebo
|
Subjects will be orally administered placebo once daily after breakfast for seven days.
|
EXPERIMENTAL: 1
OPC-41061
|
Subjects will be orally administered OPC-41061 7.5 mg or 15 mg once daily after breakfast for seven days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Body Weight
Time Frame: Baseline, at the time of final trial drug administration
|
The body weight change from baseline at the time of final trial drug administration
|
Baseline, at the time of final trial drug administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2007
Primary Completion (ACTUAL)
January 1, 2009
Study Completion (ACTUAL)
January 1, 2009
Study Registration Dates
First Submitted
September 3, 2007
First Submitted That Met QC Criteria
September 3, 2007
First Posted (ESTIMATE)
September 5, 2007
Study Record Updates
Last Update Posted (ESTIMATE)
December 25, 2013
Last Update Submitted That Met QC Criteria
November 6, 2013
Last Verified
November 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 156-06-004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiac Edema
-
Otsuka Pharmaceutical Co., Ltd.RecruitingCardiac Edema (CHF)Japan
-
Otsuka Beijing Research InstituteCompleted
-
Taiwan Otsuka Pharm. Co., LtdCompletedCardiac-induced EdemaTaiwan
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Biobeat Technologies Ltd.CompletedAcute Cardiac Event | Acute Cardiac Failure | Acute Cardiac Pulmonary EdemaIsrael
-
Emergency Medical Service of the Central Bohemian...Masaryk Hospital Usti nad Labem; Institute of Experimental Physics, Slovak...Completed
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Fondazione Policlinico Universitario Agostino Gemelli...Active, not recruiting
-
Indiana UniversityVanderbilt UniversityTerminatedHeart Failure | Acute Cardiac Failure | Acute Cardiac Pulmonary Edema | Heart Failure AcuteUnited States
-
Indiana UniversityWayne State University; Vanderbilt University; Case Western Reserve University; Inova Fairfax HospitalCompletedHeart Failure | Acute Cardiac Failure | Acute Cardiac Pulmonary Edema | Heart Failure AcuteUnited States
Clinical Trials on OPC-41061(Tolvaptan)
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Otsuka Pharmaceutical Development & Commercialization...TerminatedHyponatremia | Inappropriate ADH Syndrome | Dilutional HyponatremiaUnited States
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAutosomal Dominant Polycystic Kidney DiseaseUnited States
-
Otsuka Pharmaceutical Development & Commercialization...RecruitingAutosomal Recessive Polycystic Kidney Disease (ARPKD)United States, Belgium, Spain, Germany, United Kingdom, Poland
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Otsuka Pharmaceutical Development & Commercialization...CompletedChronic Kidney Disease | Autosomal Dominant Polycystic Kidney DiseaseAustralia, Belgium, Italy, Spain, Sweden, United States, Canada, Netherlands, Czechia, Poland, Germany, Russian Federation, Hungary, Israel, Puerto Rico, Argentina, Denmark, South Africa, United Kingdom, Norway, France, Romania
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAutosomal Dominant Polycystic Kidney DiseaseUnited States
-
Otsuka Pharmaceutical Co., Ltd.Completed
-
Otsuka Pharmaceutical Co., Ltd.CompletedEdema | Heart Failure, CongestiveJapan
-
Otsuka Pharmaceutical Development & Commercialization...Otsuka Pharmaceutical Co., Ltd.CompletedPolycystic Kidney Disease, Autosomal DominantUnited States, Belgium, United Kingdom, Russian Federation, France, Australia, Netherlands, Italy, Japan, Denmark, Romania, Poland, Canada, Argentina, Germany